Abbott’s medical device sales hit by China curbs, supply-chain issues
The multinational healthcare giant recorded overall medical device sales of $3.75 billion, missing analysts’ average estimate of $3.84 billion.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Sen. Warren leads call for prostate cancer drug pricing reform
/in TherapeuticsA group of 25 senators, led by Sen. Elizabeth Warren (D-MA), requested that HHS Sec. Xavier Becerra exercise march-in rights for Xtandi, a prostate cancer therapeutic. March-in rights give the government the right to take a license for itself if it helped to fund the product owner’s research.
Merck scraps Keytruda trial for prostate cancer after dismal interim data
/in R&D, TherapeuticsThe drug was being tested in combination with androgen deprivation therapy and Xtandi, made by Pfizer Inc and Astellas Pharma Inc., in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.
Cidara Therapeutics and Melinta Therapeutics announce FDA Advisory Committee recommends approval of Rezafungin for the treatment of candidemia and invasive candidiasis
/in TherapeuticsIC continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive candidiasis in over a decade.
CDC chief to create new offices to boost public health response – Bloomberg News
/in TherapeuticsThe new office is aimed at closing up crucial gaps in monitoring for potential threats, according to a Bloomberg report, which cited a person who attended a town hall held yesterday at the agency’s headquarters in Atlanta.
Investing in the future means investing in data
/in February 2023, Issue Archives, Marketing & Advertising, TherapeuticsAlthough the pandemic gave a boost to the drug discovery market, accelerated development in the market will be influenced by effective use of data and analytics.
Thermo Fisher Scientific partners with AstraZeneca to develop solid tissue and blood-based companion diagnostic test for Tagrisso
/in Business, R&D, TherapeuticsThrough ongoing collaboration, new companion diagnostic aims to deliver next-generation sequencing results in as little as 24 hours to help advance precision oncology.
Neurofilament biomarker to face key test at Biogen-Ionis’ Tofersen Adcomm
/in Issue ArchivesThe FDA’s Peripheral and Central Nervous System Drugs advisory committee will discuss the merits of Biogen and Ionis’s ALS candidate tofersen on March 22nd.
Pliant seeks $175 M raise on heels of promising mid-stage IPF data
/in R&D, TherapeuticsCompany president and CEO Bernard Coulie, M.D., Ph.D. called the data “unprecedented in IPF clinical drug development”.
J&J forecasts 2023 profit above expectations on pharma strength
/in Business, TherapeuticsJ&J’s large pharmaceuticals business is its major profit engine and the company is betting on that and its devices unit as the healthcare conglomerate prepares to spin off its consumer health business by the end of this year.